Results 1 to 10 of about 295,419 (335)

Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

open access: yesFrontiers in Pharmacology, 2022
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, some drug use addictions, as well as depression.
Fangyi Zhao   +9 more
doaj   +1 more source

The Genetic Underpinnings of Affective Temperaments: Identifying Novel Risk Variants with a Whole Genome Analytical Approach

open access: yesEuropean Psychiatry, 2022
One reason behind the failure to understand the neurobiological background of affective disorders and develop more effective treatments is their heterogeneity warranting identification of clinically meaningful endophenotypes.
X. Gonda   +7 more
doaj   +1 more source

Association of genetic variants of Glutamate Metabotropic Receptor 5 gene and state-anhedonia

open access: yesEuropean Psychiatry, 2022
Introduction Andedonia is one of the core symptoms of depression. It is known that in case of depressed individuals experiencing anhedonia, the classical antidepressants are often ineffective, thus investigation of this symptom would be essential ...
D. Török   +6 more
doaj   +1 more source

Genetic underpinnings of affective temperaments: a pilot GWAS investigation identifies a new genome-wide significant SNP for anxious temperament in ADGRB3 gene

open access: yesTranslational Psychiatry, 2021
Although recently a large-sample GWASs identified significant loci in the background of depression, the heterogeneity of the depressive phenotype and the lack of accurate phenotyping hinders applicability of findings.
Xenia Gonda   +11 more
doaj   +1 more source

Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems

open access: yesFrontiers in Cell and Developmental Biology, 2022
Depression has an alarmingly high prevalence worldwide. A growing body of evidence indicates that environmental factors significantly affect the neural development and function of the central nervous system and then induce psychiatric disorders.
Ziqian Cheng   +7 more
doaj   +1 more source

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea

open access: yesFrontiers in Aging Neuroscience, 2023
BackgroundVortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a ...
Eduardo Cumbo   +3 more
doaj   +1 more source

The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain

open access: yesFrontiers in Psychiatry, 2022
Depression is a common and often recurrent illness with significant negative impact on a global scale. Current antidepressants are ineffective for up to one third of people with depression, many of whom experience persistent symptomatology.
Angharad N. de Cates   +18 more
doaj   +1 more source

Experimental pharmacological research regarding the antidepressant effect of associating doxepin and selegiline in normal mice [PDF]

open access: yes, 2019
The severity and complexity of depression can vary widely among individuals, thus making single drug therapy ineffective in some cases. Taking this fact into account and using a mouse model, we set on investigating the possibility of obtaining a ...
Chiriță, Cornel   +8 more
core   +2 more sources

Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors [PDF]

open access: yes, 2017
Nearly 30% of intensive care unit (ICU) survivors have depressive symptoms 2-12 months after hospital discharge. We examined the prevalence of depressive symptoms and risk factors for depressive symptoms in 204 patients at their initial evaluation in the
Boustani, Malaz   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy